Evidence map›Paper›PMID 39982072›Full record

ArticleAntimicrobial agents and chemotherapy2025

A link between aging and persistence.

A M Proenca, C U Rang, L Chao

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A M ProencaImmunology and Microbiology Laboratory, School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID 0000-0002-3747-9719
C U RangSection of Ecology, Behavior and Evolution, Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA.
L ChaoSection of Ecology, Behavior and Evolution, Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA.ORCID 0009-0005-4114-5841

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Program for Institutional Internationalization Postdoctoral FellowshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Science Without Borders FellowshipNational Science Foundation (NSF) DEB-1354253
6 · The paper itself

Abstract

Despite the various strategies that microorganisms have evolved to resist antibiotics, survival to drug treatments can be driven by subpopulations of susceptible bacteria in a transient state of dormancy. This phenotype, known as bacterial persistence, arises due to a natural and ubiquitous heterogeneity of growth states in bacterial populations. Nonetheless, the unifying mechanism of persistence remains unknown, with several pathways being able to trigger the phenotype. Here, we show that asymmetric damage partitioning, a form of cellular aging, produces the underlying phenotypic heterogeneity upon which persistence is triggered. Using single-cell microscopy and microfluidic devices, we demonstrate that deterministic asymmetry in exponential phase populations leads to a state of growth stability, which prevents the spontaneous formation of persisters. However, as populations approach stationary phase, aging bacteria-those inheriting more damage upon division-exhibit a sharper growth rate decline, increased probability of growth arrest, and higher persistence rates. These results indicate that persistence triggers are biased by bacterial asymmetry, thus acting upon the deterministic heterogeneity produced by cellular aging. This work suggests unifying mechanisms for persistence and offers new perspectives on the treatment of recalcitrant infections.

Indexed as

Bacterial Physiological PhenomenaEscherichia coliAnti-Bacterial AgentsLab-On-A-Chip DevicesPhenotypeSingle-Cell AnalysisAnti-Bacterial AgentsagingEscherichia colimicrofluidicspersistence

Identifiers

PMID39982072
PMCPMC11963536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.